




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Alawi, K. M., Aubdool, A. A., Liang, L., Wilde, E., Vepa, A., Psefteli, M-P., Brain, S. D., & Keeble, J. E. (2015).
The sympathetic nervous system is controlled by transient receptor potential vanilloid 1 in the regulation of body
temperature. Faseb Journal, 29(10). https://doi.org/10.1096/fj.15-272526
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 23. Jan. 2021
The FASEB Journal • Research Communication
The sympathetic nervous system is controlled by transient
receptor potential vanilloid 1 in the regulation of
body temperature
Khadija M. Alawi,*,† Aisah A. Aubdool,† Lihuan Liang,† Elena Wilde,† Abhinav Vepa,*
Maria-Paraskevi Psefteli,* Susan D. Brain,† and Julie E. Keeble*,1
*Institute of Pharmaceutical Science and †British Heart Foundation Cardiovascular Centre of Excellence
and Centre of Integrative Biomedicine, Cardiovascular Division, King’s College London, London,
United Kingdom
ABSTRACT Transient receptor potential vanilloid 1
(TRPV1) is involved in sensory nerve nociceptive sig-
naling. Recently, it has been discovered that TRPV1
receptors also regulate basal body temperature in mul-
tiple species frommice to humans. In the present study,
we investigated whether TRPV1 modulates basal sym-
pathetic nervous system (SNS) activity. C57BL6/J wild-
type (WT) mice and TRPV1 knockout (KO) mice were
implanted with radiotelemetry probes for measurement
of core body temperature. AMG9810 (50 mg/kg) or
vehicle (2% DMSO/5% Tween 80/10 ml/kg saline)
was injected intraperitoneally. Adrenoceptor antago-
nists or vehicle (5 ml/kg saline) was injected sub-
cutaneously. In WT mice, the TRPV1 antagonist,
AMG9810, caused significant hyperthermia, associ-
ated with increased noradrenaline concentrations in
brown adipose tissue. The hyperthermia was signifi-
cantly attenuated by the b-adrenoceptor antagonist
propranolol, the mixed a-/b-adrenoceptor antagonist
labetalol, and the a1-adrenoceptor antagonist prazosin.
TRPV1 KOmice have a normal basal body temperature, in-
dicative of developmental compensation. D-Amphetamine
(potent sympathomimetic) caused hyperthermia in
WT mice, which was reduced in TRPV1 KO mice, sug-
gesting a decreased sympathetic drive in KOs. This
study provides new evidence that TRPV1 controls ther-
moregulation upstream of the SNS, providing a potential
therapeutic target for sympathetic hyperactivity thermo-
regulatory disorders.—Alawi, K.M., Aubdool, A. A., Liang,
L., Wilde, E., Vepa, A., Psefteli, M.-P., Brain, S. D., Keeble,
J. E. The sympathetic nervous system is controlled
by transient receptor potential vanilloid 1 in the regulation
of body temperature. FASEB J. 29, 4285–4298 (2015).
www.fasebj.org
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Transient receptor potential vanilloid 1 (TRPV1) is a non-
selective cation channel, predominantly expressed on peri-
vascular sensory neurons (1). It is widely considered as an
integrator of noxious stimuli, including capsaicin, noxious
heat, and acid conditions, among others. TRPV1 channels
presented a novel target for pharmacologic manipulation
for inflammatorypainconditions(1,2).Morerecently, ithas
been found that TRPV1 plays a fundamental role in basal
body temperature regulation in a variety of species from
mice to humans (3, 4). Acute inhibition of TRPV1 causes
hyperthermia, reaching a body temperature of ;40°C
in 1 human subject. However, the precise mechanisms
underlying this hyperthermia are not fully understood.
Mammalianbody temperature is regulatedconstantly by
a fine balance between heat loss and generation (5);
thermoregulatory homeostasis is achieved via behavioral
and physiologic effector responses. This is principally
achievedby theautonomicnervous system, through intricate
circuits involving peripheral thermosensors and the CNS
tomediate effectormechanisms in response to changes
in the ambient temperature (6). Cold exposure stim-
ulates the sympathetic nervous system (SNS), where
heat-gain mechanisms involving thermogenesis in brown
adipose tissue (BAT) are activated (6). Additional effector
responses include cutaneous constriction, thereby com-
bining heat production via BAT-derived thermogenesis,
and retention of heat via cutaneous constriction (6).
However, BAT-mediated thermogenesis is the most po-
tent thermogenic effector mechanism and is exclusively
mediated by uncoupling protein (UCP)1, downstream of
b-adrenoceptor activation (7). This process induces and
activates mitochondrial UCP1, which uncouples oxidative
Abbreviations: AUC, area under the curve; BAT, brown adi-
pose tissue; Dio2, type II iodothyronine deiodinase; DSI, Data
Science International; GM, gastrocnemius; HPRT, hypoxanthine
phosphoribosyltransferase; HPT, hypothalamic-pituitary-thyroid;
HRP, horseradish peroxidase; KO, knockout; MDMA, methyl-
enedioxy methamphetamine; NA, noradrenaline; PGC1-a,
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phosphorylation from ATP production, releasing chem-
ical energy as heat (8). AlthoughBAT has been previously
considered tobepresent innewbornhumans, inaddition to
a fundamental role in rodents, hibernating mammals (9),
BAT has now been shown to be functionally expressed in
adults (10, 11). Additionally, humans with metabolically
active BAT depots respond to ab3-adrenoceptor agonist,
which stimulated BAT metabolic activity and enhanced
global metabolism (12).
Hyperthermia, induced by TRPV1 inhibition, has been
shown to result in increasedoxygen consumption, coupled
with tail skin vasoconstriction in rodents, which are char-
acteristic thermoeffectors downstream of autonomic ac-
tivity (13). This suggests that the hyperthermia associated
with TRPV1 inhibition mimics sympathetically mediated
thermogenesis.
As inhibition of TRPV1 results in hyperthermia, it was
expected that TRPV1 knockout (KO) mice would exhibit
altered thermoregulatory pathways. However, TRPV1 KO
mice do not exhibit gross differences in their core body
temperatures under neutral ambient conditions (3). A sim-
ilarphenomenonisobserved inwild-type(WT)mice thatare
chronically treated with TRPV1 antagonist (14), suggesting
that sympathetic drive has been reduced as a compensatory
mechanismtonormalizebody temperature in theseanimals.
In the present study, we have used a pharmacological
approach, using the TRPV1 antagonist, AMG9810, to
investigate theroleofTRPV1inbasalbody thermoregulation.
We subsequently sought to explore the thermoregulatory
profile of TRPV1 KO mice. Based on all of the current evi-
dence discussed above, we tested the hypotheses that TRPV1
inhibition results in hyperthermia due to disinhibition of the
SNS and that TRPV1 KO mice exhibit a suppressed sympa-
thetic drive to maintain thermoregulatory homeostasis.
MATERIALS AND METHODS
Ethics statement
All experiments were conducted in accordance with the United
Kingdom Home Office Animals (Scientific Procedures) Act 1986
andAmendmentRegulations2012.Theywerealsoapprovedby the
King’s College London Animal Welfare and Ethical Review Body.
Animals
Malemice (8–15wk of age)were used for all experiments. Animals
were housed in temperature- (226 2°C) and humidity-controlled
(50 6 10%) colony rooms maintained under filtered positive
pressure ventilation on a 12-h light-dark cycle beginning at 7:00 AM
Greenwichmean timewith freeaccess towater and food.Male, age-
matched C57BL6/129SvJ WT and TRPV1 homozygous KO mice
(with .7 generations of backcrosses) were used at 8 wk of age.
TRPV1 KO mice were generated by replacing the exon, which
encodes part of the fifth and entire sixth transmembrane domain
(15). The genotype of each animal was established by PCR as pre-
viously described (16, 17). All recovery procedureswere performed
under isofluraneanesthesia (2%volumeisofluraneand2%volume
O2) for induction andmaintenance. Blood samples were collected
via the left ventricle of the heart by cardiac puncture to obtain
plasma; animals were killed by cervical dislocation under anesthe-
sia. Plasma was separated by centrifugation (2000 g for 20 min).
Radiotelemetry surgical implantation
MaleWTandTRPV1KOwereused for all remote radiotelemetry
studies, as previously described (18). Buprenorphine analgesia
was administered intramuscularly perioperatively (10 mg/kg;
Vetersergic; Sogeval, Sheriff Hutton, United Kingdom). Mice
were anesthetized (2–3% volume isoflurane carried in 2–3%
volume O2), the abdomen was shaved and scrubbed using sur-
gical iodine, and the mice were placed on a homeothermic
heatingmat. A small ventralmidline abdominal incision (,1 cm)
wasmade, and the abdominalmuscle wall was exposed. A ventral
incision was made on the abdominal wall and was irrigated with
sterile saline (0.9% saline; sodium chloride, pyrogen free) to fa-
cilitate the insertion of the radiotelemetry transmitter [TA10TA-
F10; Data Science International (DSI), St. Paul, MN, USA]. Fol-
lowing implantation, the abdominal wall and the skin incision
were sutured separately using absorbable sutures (Vicryl 4.0;
Ethicon, Johnson & Johnson, New Brunswick, NJ, USA). The
mice were monitored until ambulatory in an incubator main-
tained at 26°C and were then individually housed with food and
water ad libitum. Animals were allowed at least a 7 d postsurgical
recovery period. Cages containing the telemetered animals were
placed on the receiver plates (RPC-1; DSI); radio signals from the
implanted transmittersweremonitoredvia a fully automateddata
acquisition system(DataquestA.R.T., version4.1;DSI).Corebody
temperature and locomotor activity were monitored for 10 min
intervals, for durations of 120 s. Core body temperature and ac-
tivityweremonitoreddaily; baselinemeasurementswere recorded
for at least 60minpretreatment.Datawere collected andanalyzed
inMicrosoft Excel (Microsoft, Redmond,WA, USA) andGraphPad
Prism 5 (GraphPad Software, La Jolla, CA, USA).
Acute immobilization studies
WT mice were anesthetized with ketamine (75 mg/kg) and
medetomidine(1mg/kg).Allmicewereplacedonaheatblanket,
the temperature of which was determined by homeothermically
coupling it to control, untreated mice. A temperature microchip
transmitter (LifeChip; Destron Fearing, Eagan, MN, USA) was
inserted intraperitoneally followinga small incision to the skinand
abdominal layer; the incisions were sutured as described pre-
viously. Body temperature was monitored every 15 min, and fol-
lowing a baseline period, AMG9810 (50 mg/kg; 5 ml/kg, i.p.) or
vehicle (2% DMSO, 5% Tween 80 in saline) was administered.
Body temperature was monitored for 120 min thereafter.
Drugs
All agents were from Sigma-Aldrich (Poole, United Kingdom),
unless stated otherwise. Doses of drugs administered were
obtained from literature or optimized from published doses.
Adrenoceptor antagonists or control was administered sub-
cutaneously 30 min prior to administration of the TRPV1 antag-
onist AMG9810 (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b]
[1,4] dioxin-6-yl)acrylamide) [50 mg/kg; 10 ml/kg, i.p. (19)] or
vehicle (2% DMSO, 5% Tween 80 in saline; 10 ml/kg, i.p.). Pro-
pranolol hydrochloride [5 mg/kg (20)], labetalol hydrochloride
(continued from previous page)
proliferator-activated receptor g coactivator 1-a; pNPP,
p-nitrophenyl phosphate; PPAR-g, peroxisome proliferator-
activated receptor g; qPCR, quantitative PCR; SNS, sympathetic
nervous system; TRPV1, transient receptor potential vanilloid 1;
UCP, uncoupling protein; VDAC, voltage-dependent anion-
selective channel; WT, wild-type
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[30mg/kg (21,22)],prazosinhydrochloride[0.1mg/kg(23)], ICI
118,551 hydrochloride [10 mg/kg (24)], and metoprolol hydro-
chloride [20mg/kg (25)] were dissolved in saline. The selectiveb3-
adrenoceptor antagonist SR59230A (2S)-1-(2-ethylphenoxy)-
3-[[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]propan-2-ol
[2.5 mg/kg (26)] was dissolved in 2%DMSO and suspended in
saline. In separate experiments, D-amphetamine hemisulfate
was suspended in saline and administered subcutaneously at
a dose of 10mg/kg (27). Because circadian factors are known to
influence core body temperature, all dosing was initiated be-
tween 12:00 PM and 1:00 PM. Treatments were randomized, and
the experimenter was blinded to the genotype of animals at the
time of experiments.
Calculation of the hyperthermic index
For each animal, the area under the curve (AUC) for tempera-
turewas calculatedusingGraphPadPrism5 software.Briefly, data
for 60min pretreatment were used as amean baseline reading to
calculate individual AUC values utilizing the analysis function
providedby the software. The timepoints analyzed corresponded
to each hour posttreatment, and the results from individual mice
were grouped, analyzed, and presented as a hyperthermic index
(°C 3 min) or activity index (activity counts 3 min), for studies
using D-amphetamine.
Quantification of noradrenaline concentrations
Noradrenaline (NA) concentrations were measured using
a commercially available NA ELISA kit (IBL International,
Hamburg, Germany), as previously described (28). Tissue was
collected in a sterile environment and snap frozen at280°Cuntil
processing.Tissuewashomogenized in lysisbuffer [RIPA;1%NP-
40, 0.1% sodiumdodecyl sulfate, 50mMTris-HCl, 150mMNaCl,
0.5% sodium deoxycholate, and 1 mM EDTA (pH 7.4)] con-
taining protease inhibitors (1 tablet/50 ml; Roche Diagnostics,
Burgess Hill, United Kingdom), and lysates were obtained by
centrifuging at 2600 g for 10 min at 4°C. According to the man-
ufacturer’s instructions, 20 ml tissue lysates, standards, and con-
trols was added to extraction plates. After extraction, bound NA
(25ml)waselutedusing releasebuffer and transferred toa96well
ELISA plate. A total of 50ml NA antiserumwas incubated with all
samples at room temperature for 120 min on an orbital shaker;
the plates were thoroughly washed with diluted washing buffer,
and 100 ml enzyme conjugate was added into each well and in-
cubated for 60 min at room temperature. Following several
washes, 200 ml p-nitrophenyl phosphate (pNPP) substrate solu-
tion was incubated at room temperature for 40 min, and the
reactions were stopped by addition of 50 ml pNPP stop solution
per well. The optical densities of each well weremeasured at 405
nm, and a standard curve was plotted using a range of knownNA
concentrations provided in the kit (0, 5, 15, 50, 150, and
500 ng/ml). Positive and negative controls were included to
determine accuracy. The limit of sensitivity was 20 pg/ml, and
the linearity limit was 8.0 ng/ml. Cross-reactivity to other cat-
echolamines or metabolites was manufacturer tested as,0.02%.
Protein concentrationsof each sampleweredeterminedusing the
Bradford dye-binding method (Bio-Rad, Hemel Hempstead,
United Kingdom), and NA concentrations of each sample were
normalized to milligrams of protein and expressed as NA
(nanograms per milligram of tissue protein) (29).
Measurement of plasma cytokines
At 2 h post-AMG9810, blood samples were collected to obtain
plasma under isoflurane anesthesia (2–3% volume isoflurane
carried in 2–3% volume O2). Mouse TNF-a, IL-6, and IL-1b
ELISA kits (Invitrogen, Life Technologies, Paisley, United
Kingdom) were used to quantify plasma concentrations accord-
ing to the manufacturer’s instructions. Briefly, 50–100 ml stan-
dard, controls, and plasma samples was loaded into the wells.
Subsequently, 50 ml biotinylated secondary antibody was added,
and plates were incubated at 37°C for 120–180 min. Plates were
washed, and 100 ml streptavidin-horseradish peroxidase (HRP)
was added to each well and incubated at room temperature for
a further 30 min. Stabilized chromogen (100 ml) was added to
eachwell, and the plates were incubated in the dark for 30min at
room temperature. The reaction was stopped with the addition
of 100 ml stop solution. The optical densities of each well were
measured at a wavelength of 450 nm, and a standard curve was
generated to calculate the sample cytokine concentrations. The
limit of sensitivity was ,3 pg/ml, and the linearity limit was
6 pg/ml. Cross-reactivity to other cytokines was manufacturer
tested as ,0.01%.
Quantitative PCR
RNA was extracted from BAT and gastrocnemius (GM) samples
using the Qiagen RNeasy Microarray kit (Qiagen, Crawley,
United Kingdom) following the manufacturer’s instructions.
RNA was quantified by optical density measurements on
a Nano-Drop 8000 Spectrophotometer (Thermo Scientific,
Loughborough, United Kingdom). Total RNA (0.5–1 mg) was
reverse transcribed using the high-capacity RNA-to-cDNA kit
supplemented with RNAse inhibitor according to the manu-
facturer’s instructions (Applied Biosystems, Life Technologies)
in a 20 ml reaction volume. Quantitative PCR (qPCR) was per-
formed with the SensiMix SYBRNo-ROXKit (Bioline, London,
United Kingdom) with Hot-Start Taq polymerase on a Corbett
Rotorgene using predesigned primers from Sigma-Aldrich
(Table 1). Samples were heated to 95°C for 10 min (initial
denaturation), followed by 45 cycles of 10 s at 95°C, 15 s at 57°C,
and 5 s at 72°C; melt was 68–90°C with fluorescence detection
after each cycle. Samples were subjected to melting curve
analysis to confirm amplification specificity. Samples were
normalized to hypoxanthine phosphoribosyltransferase (HPRT)
and expressed as relative fold change using the DDCt method of
relative quantification as described byLivak and Schmittgen (30).
Immunoblotting
Interscapular BAT and GM frommale TRPV1 WT and KOmice
and WT mice administered with AMG9810 or vehicle were im-
mediately dissected and snap frozen in liquid nitrogen for mito-
chondrial protein extraction using a Mitochondria Isolation Kit
(Thermo Scientific) according to the manufacturer’s instruc-
tions. Equal amounts of protein (15–30 mg) were separated by
SDS-PAGE under reducing conditions in 10% polyacrylamide
gels. The proteins were transferred to PVDF membranes (EMD
Millipore, Feltham, United Kingdom), blocked in 5% nonfat
dried milk (1 h at room temperature), and incubated with pri-
mary antibody forUCP1 andUCP3 (1:1000 ab23841 and ab3477;
Abcam, Cambridge, United Kingdom) at 4°C for 12 h. The
voltage-dependent anion-selective channel (VDAC) was used as
a loading control (1:1000 AB10527; EMD Millipore). The
membranes were exposed under ECL (Luminata Classico
Western HRP substrate; EMD Millipore) in a G-BOX Gel Doc-
umentation System (Syngene, Cambridge, United Kingdom)
using the manufacturer’s software (Syngene 2D gel imaging
software; Syngene). Samples were quantified densitometri-
cally using ImageJ (National Institutes of Health, Bethesda,
MD, USA).
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Histologic assessment of BAT
Intrascapular BAT pads were fixed in 4% paraformaldehyde in
PBS, embedded in paraffin, and 10mmsections were assessed for
general morphology using hematoxylin and eosin staining, as
described by Shimizu et al. (31). Large lipiddroplets weredefined
as lipids.25mm,measuredwith ImageJ, andcountedperfield at
3200 magnification. A minimum of 10 fields was randomly se-
lected from each sample (n = 4–6 mice per experimental
group), and results are presented as lipid droplets (micro-
meters per field).
Analysis
Results are presented as means 6 SEM. Statistical differences be-
tween samples were determined by either unpaired Student’s t
test or 2-way ANOVA and Bonferroni post hoc test using the
GraphPad Prism software [version 5.02 for Windows (Micro-
soft)]. P , 0.05 was considered to represent a significant
difference.
RESULTS
AMG9810-induced hyperthermia is dependent on
spontaneous activity
The initial aim of the present study was to characterize the
hyperthermia induced by the polymodal antagonist,
AMG9810, and confirm that the effect on body tempera-
ture was on target (Fig. 1A). Indeed, TRPV1KOmice were
immune to theAMG9810-inducedhyperthermia (Fig. 1B).
Additionally, analysis of activity levels in WT mice showed
a sustained increase in spontaneous activity in AMG9810-
treated mice (Fig. 1A, C), whereas vehicle-treated mice
exhibited a transient increase in activity associated with the
injection artifact. This increase in activity (hyperkinesis) is
in agreement with previousfindings by other authors (18).
Thus, to establish the contribution of spontaneous activity
to the hyperthermia, AMG9810 was administered to
anesthetized mice (Fig. 1D). AMG9810 failed to elicit the
typical acute hyperthermia in these mice, demonstrating
a positive relationship between spontaneous activity and
hyperthermia.
The clinical distinction between fever andhyperthermia
is the disruption of the thermoregulatory set point in the
former, typically cytokine driven (32), whereas hyperther-
mia involves deficits in thermoregulatory mechanisms
such as heat dissipation with no implication of central
mechanisms. Plasma cytokine concentrations were mea-
sured 2 h posttreatment withAMG9810, and no significant
increase in IL-6, TNF-a, or IL-1b concentrations was ob-




As it was established that AMG9810 induces a pharmaco-
logic hyperthermia, as opposed to cytokine-induced fever,
we hypothesized that TRPV1 antagonist-induced hyper-
thermia involves activation of the SNS. To test this hy-
pothesis, NA concentrations weremeasured inWTmice at
the peakonset of thehyperthermia, 1 hposttreatmentwith
AMG9810 or vehicle. The NA content of brain samples
from AMG9810 compared with vehicle-treated mice did
not differ (Fig. 2A), suggesting a lack of central NA activity
in this hyperthermia. Additionally, kidney NA concentra-
tionswereunaltered (48.5266.9vs.52.05618.90ng/ml),
suggesting no involvement of renal adrenergic pathways.
In contrast, AMG9810 caused a significant increase in the
NA content of BAT (Fig. 2B), which suggests an increase
in sympathetic activity and BAT-mediated thermogenesis.
Interestingly, a significant decrease in NA content in skin
samples of AMG9810-treated animals was observed (Fig.
2C), compared with vehicle-treated controls. A modest
increase in plasma NA concentrations in AMG9810-
treated mice compared to vehicle-treated mice was
determined (33.39 6 12.95 vs. 6.162 6 0.6045 ng/ml;
P = 0.0805; n = 5), suggesting an increase in NA outflow
to the periphery.
The transcriptional and protein levels of thermogenic
mediators under sympathetic control were determined in
TABLE 1. qPCR primer information
Target Primer sequence Accession number
Product
length (bp)
Dio2 F: TCCTAGATGCCTACAAACAGGTTA NM_010050 148
R: GCACTGGCAAAGTCAAGAAGG
HPRT F: TCCTCCTCAGACCGCTTTT NM_013556.2 90
R: CCTGGTTCATCATCGCTAATC
PGC1-a F: CCACAGAAAACAGGAACAGCAG NM_008904.2 142
R: CCCTTGGGGTCATTTGGTGA
PPAR-g F: GCCTATGAGCACTTCACAAGAAAT NM_001127330 173
R: TGCTGGAGAAATCAACTGTGGT
UCP1 F: GAGGTGTGGCAGTGTTCATT NM_009463 112
R: TAAGCATTGTAGGTCCCCGTGT
UCP2 F: AGATGTGGTAAAGGTCCGCTTC NM_011671.4 90
R: GCAATGGTCTTGGTAGGCTTC
UCP3 F: TTCCCCTGTCACTTTGTCTCTG NM_009464.3 85
R: ATCGGGTCTTTACCACATCCAC
F, forward; R, reverse.
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BAT additionally, in skeletal muscle. Assessment of UCP1
in BAT demonstrated an induction in AMG9810-treated
mice (Fig. 2D, E); however, this did not reach significance.
AlthoughUCP1 is themost potent thermogenic protein in
mammals, a skeletal muscle-abundant homolog, UCP3, is
additionally involved in nonshivering thermogenesis (33).
A significant induction in UCP3 levels was observed inWT
mice administered with AMG9810 in comparison with
control (Fig. 2F, G).
Assessment of relative mRNA expression in BAT and
GM samples of WT mice administered with AMG9810 or
vehicle (Table 2) demonstrated no alteration in UCP1
expression. However, a significant induction of the tran-
scription coactivator, peroxisome proliferator-activated re-
ceptor g coactivator 1-a (PGC1-a), in BAT samples from
AMG9810-treated mice was observed. It is known that
the expression of UCP1 is highly fluidic and is driven by
several transcriptional components, including PGC1-a
(34). PGC1-a is known to regulate oxidative meta-
bolism by increasing mitochondrial gene expression
and function (35). Peroxisome proliferator-activated
receptor-g (PPAR-g), a regulator of UCP1 expression
(34), was unaffected by AMG9810. In contrast, a signif-
icant induction of type II iodothyronine deiodinase
(Dio2) was observed, implicating the hypothalamic-
pituitary-thyroid (HPT) axis in AMG9810-induced
hyperthermia.
Adrenoceptors contribute to AMG9810-
induced hyperthermia
To determine the contribution of postjunctional adreno-
ceptors to the hypothermia induced by AMG9810, we
pretreated mice with adrenoceptor antagonists prior to
challenging them with AMG9810. The acute temperature
increase followingAMG9810 administrationdemonstrated
that the hyperthermia was sustained from 60 to 200 min
posttreatment (Fig. 3A). The nonselective b-adrenoceptor
antagonist, propranolol, delayed the onset of AMG9810-
induced hyperthermia (120 min), compared to saline-
pretreated mice (Fig. 3A). Analysis of the AUC for the
hyperthermic period (defined as the hyperthermia in-
dex) demonstrated a significant difference between
control-pretreated and propranolol-pretreated mice
(Fig. 3B). Similarly, the mixed a-/b-adrenoceptor an-
tagonist, labetalol (36), resulted in a marked delay in the
onset of the AMG9810-induced hyperthermia (Fig. 3C)
and a significant reduction in the hyperthermic index
(Fig. 3D). To investigate the involvement of distinct sub-
types ofa- andb-adrenoceptors, selective antagonists were
consequently used. The effect of selective a1-adrenoceptor
blockade was assessed, showing that prazosin decreased
both the magnitude of the hyperthermia (Fig. 3E) and the
hyperthermia index(Fig.3F).Theseresultsare inagreement
with the role of a1-adrenoceptors in mediating cutaneous
Figure 1. AMG9810-induced hyperthermia is dependent on spontaneous activity. A) Core body temperature (top) and activity
(bottom) recordings over 360 min following AMG9810 (50 mg/kg, i.p.) or vehicle (2% DMSO, 5% Tween 80 in saline) in TRPV1
WT mice. B) Temperature (top panel) and activity (bottom panel) profile of AMG9810 in TRPV1 KO mice (n = 7–8 per group).
Arrows in (A) and (B) denote treatments. C) A 3 h average activity posttreatment (n = 7–8 per group). D) Administration of
AMG9810 or vehicle to anesthetized WT mice (n = 5–6 per group). Results are means 6 SEM. *P , 0.05 and ***P , 0.001 vs.
vehicle control using 2-way ANOVA and Bonferroni’s.
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vasoconstriction downstream of NA (37), and thus, treat-
mentwithprazosinmayhave facilitatedenhancedheat loss
in these mice. Furthermore, prazosin has previously been
shown to potently inhibit methylenedioxymethamphet-
amine (MDMA)-mediated hyperthermia in rodents (26).
Selective blockade of b1-adrenoceptors withmetoprolol
resulted in a potentiation of AMG9810-induced hyper-
thermia (Fig. 4A), where the hyperthermic index was
significantly larger in the metoprolol-pretreated group,
compared to saline-pretreated groups (Fig. 4B). Addi-
tionally, selective blockade of b2-adrenoceptors with ICI-
118,551 did not result in any effect on the hyperthermia
(Fig. 4C, D). Atypical b3-adrenoceptors were hypothesized
to be involvedbecause theywere shown to be involved in the
hyperthermia mediated by 3,4-MDMA (26). However, no
difference was observed in AMG9810-induced hyperthermia
Figure 2. Involvement of the SNS in TRPV1 antagonist-induced hyperthermia. NA concentrations measured in brain (A), BAT
(B), and skin (C) samples of WT mice 1 h posttreatment with AMG9810 (50 mg/kg, i.p.) or vehicle (2% DMSO, 5% Tween 80 in
saline) (n = 5). D) Immunoblot of UCP1 and loading control, VDAC, in BAT mitochondrial-extracted protein of AMG9810- or
vehicle (Veh)-treated mice (1 h). E) Densitometric analysis of the relative expression of UCP1/VDAC (n = 3–4). F) Immunoblot
of UCP3 and loading control, VDAC, in skeletal muscle (GM) mitochondrial-extracted protein of AMG9810- or vehicle-treated
mice (1 h). G) Densitometric analysis of the relative expression of UCP3/VDAC (n = 4). Results are means 6 SEM. *P , 0.05 and
**P , 0.01 vs. vehicle control using 2-tailed Student’s t test.
TABLE 2. Relative mRNA expression of thermogenic mediators in AMG9810 or vehicle-pretreated
TRPV1 WT and KO mice
Target Tissue WT vehicle WT AMG9810 KO vehicle KO AMG9810
UCP1 BAT 1.03 6 0.18 0.50 6 0.11 0.26 6 0.06 0.12 6 0.11
GM 1.09 6 0.28 0.94 6 0.21 0.65 6 0.10 0.92 6 0.18
UCP2 BAT 1.00 6 0.03 1.31 6 0.42 0.68 6 0.12 0.11 6 0.02
GM 0.91 6 0.69 0.62 6 0.18 0.49 6 0.21 0.70 6 0.21
UCP3 GM 1.03 6 0.17 0.63 6 0.07 0.94 6 0.04 0.44 6 0.03
GM 0.63 6 0.01 1.11 6 0.36 0.48 6 0.23 0.70 6 0.12
PGC1-a BAT 0.69 6 0.16 2.07 6 0.48** 0.97 6 0.22 0.61 6 0.10##
GM 1.02 6 0.16 0.74 6 0.01 0.79 6 0.39 1.13 6 0.26
PPAR-g BAT 1.01 6 0.10 1.47 6 0.30 1.37 6 0.19 0.86 6 0.11
GM 1.57 6 0.80 0.96 6 0.29 0.72 6 0.26 0.56 6 0.31
Dio2 BAT 1.21 6 0.49 3.03 6 0.30*** 2.14 6 0.48 1.25 6 0.28###
GM 1.16 6 0.36 1.41 6 0.27 0.72 6 0.07 1.70 6 0.24
Results are means 6 SEM. n = 3–5, normalized to HPRT, relative to WT vehicle mice. **P , 0.01 and
***P , 0.001 vs. control; ##P , 0.01 and ###P , 0.001 WT AMG910 as determined by 2-tailed Student’s
t test.
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following pretreatment with theb3-antagonist, SR59230A,
or vehicle (Fig. 4E, F).
Thermoregulatory phenotype of TRPV1 KO mice
at baseline
At baseline conditions, TRPV1 KO mice exhibit a normal
body temperature as previously reported (3, 13, 15); we
confirmed this bymeasuringcorebody temperatureunder
ambient conditions and observed minimal differences in
core body temperature results (Fig. 5A). Additionally,
TRPV1 KO mice demonstrate hyperkinesis during the
light phase (18), a characteristic of thermoregulatory im-
balance, which was observed in our results (Fig. 5B, C).
During the dark phase, both groups exhibited equal levels
of nocturnal activity (Fig. 5D).
Suppressed sympathetic drive in TRPV1 KO mice
It is established that TRPV1 KO mice are immune to the
hyperthermia induced by TRPV1 antagonists, and indeed,
the data presented in this study confirm the selectivity of
TRPV1 antagonist-induced hyperthermia. However, the
thermoregulatory response of TRPV1 KO mice to other
pharmacologic modulators of core body temperature has
not been established. Amphetamines are potent sym-
pathomimetics known to cause substantial hyperthermia
in multiple species (38); we utilized D-amphetamine as
a positive control and to test thehypothesis that TRPV1KO
mice exhibit a suppressed sympathetic drive. WT mice
developed hyperthermia in response to D-amphetamine
(10mg/kg),whichpeakedat120minandwas sustainedup
to 300 min postadministration of D-amphetamine (Fig.
6A). Unlike AMG9810, TRPV1 KOmice exhibited a statis-
tically significant hyperthermia compared to respective
control animals (Fig. 6A, B). However, the hyperthermia
was substantially attenuated in comparison with WT mice
administered with D-amphetamine, as evident in the hy-
perthermic index (Fig. 6B). Additionally, D-amphetamine
caused a significant increase in activity in both TRPV1WT
andKOmice (Fig. 6C,D), suggesting that the difference in
body temperature cannot solely be accounted for by
changes in activity levels. Furthermore, it is established that
the effects of D-amphetamine on body temperature and
activity are independent (39, 40).
To investigate sympathetic activity in TRPV1 KO mice,
NA concentrations were measured in naive mice. NA
concentrations were unchanged in brain samples from
TRPV1 WT and KO mice (Fig. 7A). Furthermore, no dis-
tinct differences were determined inNA concentrations in
BAT (Fig. 7B). Additionally, plasma NA concentrations
were not significantly altered (TRPV1 WT, 12.03 6 1.91
ng/ml vs. TRPV1 KO, 26.91 6 12.93 ng/ml; n = 4). How-
ever, NA concentrations were significantly reduced in skin
samples from TRPV1 KO mice, in comparison with WT
mice (Fig. 7C).
To assess the physiologic state of BAT in TRPV1 KO
mice, basal UCP1 content was measured. The results show
that UCP1 expression was decreased in mitochondrial
extracts of BAT samples of TRPV1 KOmice, compared to
WT counterparts (Fig. 7D, E), but this did not reach sig-
nificance. Interestingly, similar results were documented
Figure 3. Contribution of adrenoceptors to TRPV1
antagonist-induced hyperthermia. A) Core body
temperature recordings over 300 min following
pretreatment with propranolol (5 mg/kg, s.c.;
n = 7) or control (saline, 5 ml/kg, s.c.; n = 13).
B) The hyperthermic index was analyzed as area
under the temperature curve during the 0 to 180min
period for saline and propranolol-pretreated
mice. C) Core body temperature recordings over
300 min following pretreatment with labetalol
(30 mg/kg, s.c.; n = 8) or control (saline, 5 ml/kg,
s.c.; n = 13). D) Respective hyperthermic index
calculated for (C). E) Core body temperature
recordings over 300 min following pretreatment
with prazosin (0.1 mg/kg, s.c.; n = 7) or control
(saline, 5 ml/kg, s.c.; n = 13) followed by AMG9810
(50 mg/kg, i.p.) or vehicle (2% DMSO, 5% Tween
80 in saline) in WT mice. Arrows in (A), (C), and
(E) denote treatments. F) The respective hyperther-
mic index calculated for (E). Results are means 6
SEM. *P , 0.05, **P , 0.01, and ***P , 0.001 vs.
vehicle control; #P , 0.05, ##P , 0.01, and ###P ,
0.001 vs. AMG9810-treatedmice using 2-way ANOVA
and Bonferroni’s post hoc test.
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in sensory nerve-depleted rats (5), indicating an important
role for sensory nerves and TRPV1 channels in maintain-
ing BAT homeostasis. Skeletal muscle-derived thermo-
genesis was additionally investigated, and no distinct
differences in UCP3 levels were determined (Fig. 7F, G).
Intrascapular BAT weight was significantly increased in
TRPV1 KO mice (Supplemental Fig. 2B), independent of
body mass (Supplemental Fig. 2A). Thus, BAT mor-
phology was investigated in TRPV1 WT and KO mice,
and a whitening phenotype was observed in KO mice
Figure 4. Investigating a role for b-adrenoceptors
in TRPV1 antagonist-induced hyperthermia. A)
Core body temperature recordings over 300 min
following pretreatment with metoprolol (20
mg/kg, s.c.; n = 6) or control (saline, 5 ml/kg,
s.c.; n = 13). B) The hyperthermic index was
analyzed as area under the temperature curve
during the 0 to 180 min period for saline and
metoprolol-pretreated mice. C) Core body
temperature recordings over 300 min following
pretreatment with ICI-118,551 (10 mg/kg, s.c.;
n = 6) or control (saline, 5 ml/kg, s.c.; n = 13).
D) Respective hyperthermic index calculated for
(C). E) Core body temperature recordings over
300 min following pretreatment with SR59230A
(2.5 mg/kg, s.c.; n = 3) or control (2% DMSO
in saline, 5 ml/kg, s.c.; n = 4). Arrows in (A),
(C), and (E) denote treatments. Results are
means 6 SEM. **P, 0.01, and ***P , 0.001 vs.
vehicle control; ##P , 0.01 vs. AMG9810-
treated mice using 2-way ANOVA and Bonfer-
roni’s post hoc test.
Figure 5. Core body temperature and activity
profile of TRPV1 KO mice. Normal circadian
rhythm of temperature (A) and activity (B) of
TRPV1 WT mice (closed circles) and TRPV1
KO mice (open squares) over 24 h using radio-
telemetry (n = 9). Shaded areas in (A) and (B)
denote the dark phase. Average 12-h light-
phase activity levels (C) and average 12-h dark-
phase activity levels (D), measured in TRPV1 WT
and KO mice (n = 9). Results are means 6 SEM.
**P , 0.01 vs. WT using 2-tailed Student’s t test;
NS, not significant.
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(Supplemental Fig. 2C), with increased lipid deposition
and size. This increased lipidization is known to be asso-
ciated with reduced b-adrenoceptor signaling (31).
Analysis of relative mRNA expression of thermogenic
genes in BAT and GM demonstrated a significant down-
regulation of UCP3 in BAT samples of TRPV1 KO mice
(Table 3), whereas UCP1 exhibited a similar trend.
DISCUSSION
Basal body temperature is regulated by TRPV1 in a multi-
tude of species frommice to humans (4). Acute inhibition
of TRPV1 results in a profound hyperthermia, associated
with increased thermogenesis and skin vasoconstriction.
Therein, it would suggest that TRPV1 either tonically
promotes heat loss or suppresses heat gain mechanisms.
Chronic pharmacologic inhibition of TRPV1 leads to an
attenuation of hyperthermia (14), which corresponds
well with the normal body temperature observed in
TRPV1 KO mice. However, the compensatory mecha-
nism is currently unknown. Moreover, an understanding
of the compensatory mechanism may provide insight
into the mechanism underlying the hyperthermic re-
sponse to acute loss of TRPV1 activity, leading to an in-
creased understanding of the basal body temperature
regulation.
The initial aim of this study was to confirm that the
TRPV1 antagonist, AMG9810, increases body temperature
inmice and to verify that the effects are solely mediated by
TRPV1. To this end, we showed that AMG9810 (50mg/kg
i.p.) caused a significant increase in the body temperature
of WT mice, in accordance with previous studies using
a rangeofTRPV1antagonists fromvarious chemical classes.
TRPV1 KO mice did not develop AMG9810-induced hy-
perthermia, confirming that no off-target actions were
contributing to the effect on thermoregulation. In ad-
dition to hyperthermia, analysis of activity levels in WT
mice showed a sustained increase in spontaneous activity
in AMG9810-treated mice. This increase in activity (hy-
perkinesis) was previously shown by previous authors,
using the antagonist, AMG0347 (18). No increase in ac-
tivity was observed in KOmice in either our study or that
of previous studies (17), and the effect is not stress in-
duced because the study by Garami et al. (18) used pre-
implanted catheters to allow for drug injection without
disturbance of themice (18). Subsequent experiments in
the present study showed that mice need to be conscious
for hyperthermia to occur because AMG9810 caused no
change in body temperature in anesthetized mice. This
supports the concept that spontaneous activity may
contribute to the role of TRPV1 in thermoregulation.
Once the effect of TRPV1 inhibition on body tempera-
ture had been ratified, we aimed to investigate the contri-
bution of proinflammatory cytokines in this hyperthermia.
The involvement of cytokines in fever is well known, but
their role in hyperthermia is less clear. Sympathomimetics
such as MDMA have been shown to possess immunosup-
pressant effects (41), whereas whole-body heating did not
result in an increase in cytokines (42). Therefore, our
Figure 6. Amphetamine-induced hyperthermia is attenuated in TRPV1 KO mice. A) Core body temperature recording following
D-amphetamine (10 mg/kg, s.c.; n = 7) or vehicle (saline, 5 ml/kg, s.c.; n = 5) administration to TRPV1 WT and KO mice. B) The
hyperthermic index was analyzed as area under the temperature curve during the 120 to 290 min period for vehicle and
D-amphetamine-treated mice. C) Activity levels following D-amphetamine (10 mg/kg, s.c.; n = 7) or vehicle (saline, 5 ml/kg, s.c.;
n = 5) administration to TRPV1 WT and KO mice. D) Respective activity index analyzed as area under the activity curve during
the 120 to 290 min period. Results are means 6 SEM. *P , 0.05, **P , 0.01, and ***P , 0.001 vs. control; ###P , 0.001 vs.
genotype using 2-tailed Student’s t test and 2-way ANOVA and Bonferroni’s post hoc test.
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results establish a lack of involvement of cytokines in
TRPV1 antagonist-induced hyperthermia.
Plasma cytokine concentrations were not affected by
AMG9810 in the present study, confirming that the in-
crease in body temperature was indeed hyperthermia.
Stimulation of noradrenergic signaling in the
periphery downstream of TRPV1 antagonism
Because it was established that acute loss of TRPV1 activity
induces a pharmacological hyperthermia, as opposed to
cytokine-induced fever, we hypothesized that TRPV1 may
be tonically suppressing heat gain mechanisms. More
specifically, we hypothesized that TRPV1 tonically sup-
presses the SNS. Increased activity of the SNS initiates both
cutaneous vasoconstriction and BAT thermogenesis and is
essential for overall thermoregulation in mammals (7, 8).
Thus, we investigated concentrations of the principal
sympathetic neurotransmitter, NA, in sympathetic and
thermoregulatory organs. NA concentrations were mea-
sured inWTmice at thepeakhyperthermic period (i.e., 1 h
post-AMG9810 or vehicle). AMG9810 did not increase the
NA of the brain, although this was not surprising consid-
ering that peripheral restriction of TRPV1 antagonists in
previous studies did not prevent hyperthermia (43). In
contrast, AMG9810 significantly increased the NA content
of BAT, suggesting an increase in sympathetic activity and
subsequent BAT-mediated thermogenesis (Fig. 8). In-
terestingly, a significant decrease in NA content in skin
samples of AMG9810-treated animals was detected. NA
concentrations in the peripheral cutaneous vasculature
are tightly regulated, with acute metabolism/uptake in
order topreserve vascular tone(44).Thus, it is possible that
this reduction was facilitated by enhanced metabolism/
uptake to preserve vascular tone. Increased plasma con-
centrations of NA in AMG9810-treated mice indicated
a possibility of increased NA outflow to the periphery,
which has been previously observed in cold-induced ther-
mogenesis in rodents (45).
Having determined an increase inNAconcentrations in
BAT and plasma following acute inhibition of TRPV1 with
AMG9810, we sought to confirm the role of the SNS in the
thermoregulatory effect of TRPV1 by adrenoceptor in-
hibition. In particular, we aimed to selectively inhibit vari-
ous adrenoceptor subtypes to determine the precise
adrenoceptor responsible for the hyperthermic response to
AMG9810. Pretreatment with the selectivea1-adrenoceptor
antagonist decreased both the magnitude of AMG9810-
inducedhyperthermia and thehyperthermia index.These
results are in agreement with the role of a1-adrenoceptors
in mediating cutaneous vasoconstriction downstream of
NA (37), and thus, treatment with prazosin may have fa-
cilitated enhanced heat loss in these mice. Furthermore,
prazosin has previously been shown to potently inhibit
MDMA-mediated hyperthermia in rodents (26). How-
ever, we were unable to eliminate the possibility that the
cutaneous vasculature of our mice was maximally vaso-
constricted prior to injection of AMG9810 because the
room temperature (22°C) was subneutral for mice. In this
case, we propose that although naive mice would be max-
imally vasoconstricted at such a subneutral temperature,
a1-adrenoceptor receptor activation would not usually be
maintained in hyperthermic mice to facilitate heat loss. In
Figure 7. Suppressed sympathetic activity in TRPV1 KO mice. NA concentrations measured in brain (A), BAT (B), and skin (C)
samples of TRPV1 WT and KO mice (n = 7–8). D) Immunoblot of UCP1 and loading control VDAC in BAT mitochondrial
protein of TRPV1 WT and KO mice. E) Densitometric analysis of the relative expression of UCP1/VDAC (n = 5–6). F)
Immunoblot of UCP3 and loading control VDAC in skeletal muscle mitochondrial protein of TRPV1 WT and KO mice. G)
Densitometric analysis of the relative expression of UCP3/VDAC (n = 5–6). Results are means 6 SEM. *P , 0.05 vs. WT using
2-tailed Student’s t test.
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the case of TRPV1 antagonist-induced hyperthermia, we
propose that this a1 receptor activation is maintained,
preventing heat loss.
In contrast to prazosin, both the nonselective
b-adrenoceptor antagonist, propranolol, and mixed
a-/b-adrenoceptor antagonist, labetalol (36), resulted
in a marked delay in the onset of the AMG9810-induced
hyperthermiaandasignificantdecrease in thehyperthermic
index. Conversely, selective blockade of b1-adrenoceptors
with metoprolol resulted in a potentiation of AMG9810-
induced hyperthermia, whereas selective inhibition of
other adrenoceptor subtypes had no effect on the
AMG9810-induced hyperthermic index. In contrast to
this study, metoprolol has been previously shown to de-
crease insulin-mediated thermogenesis (46). However,
similar to TRPV1 antagonists, metoprolol decreases base-
line forearm blood flow (46) and, therefore, has the po-
tential to exacerbate the hyperthermia in this case. It was
particularly interesting that atypical b3-adrenoceptor was
not involved in AMG9810-induced hyperthermia because
it has previously been shown to be involved in 3,4-MDMA-
induced hyperthermia (26) and is considered to play
a role in lipolysis and thermogenesis (47). Thismaybedue
to compensatory effects between adrenoceptors because
micewith targeteddeletionofb1-,b2-, orb3-adrenoceptors
exhibit normal thermogenesis following a cold challenge
(48), whereas the triple KO is cold intolerant (49).Overall,
the series of experiments from the present study showed
that acute inhibition of TRPV1 causes hyperthermia via
a combination of b-adrenoceptor subtypes and sup-
ported the hypothesis that TRPV1 tonically suppresses
sympathetic activity (i.e., TRPV1 acts upstreamof the SNS
to modulate body temperature).
To further confirm the interaction between TRPV1 and
theSNS in thermoregulation,we investigated theexpression
TABLE 3. Relative mRNA expression of thermogenic mediators in
naive TRPV1 WT and KO mice
Target Tissue TRPV1 WT TRPV1 KO
UCP1 BAT 1.02 6 0.08 0.65 6 0.14
GM 1.02 6 0.10 1.23 6 0.51
UCP2 BAT 1.04 6 0.19 1.14 6 0.31
GM 1.08 6 0.26 1.01 6 037
UCP3 BAT 1.01 6 0.08 0.60 6 0.03***
GM 1.12 6 0.21 1.40 6 0.46
PGC1-a BAT 1.01 6 0.07 1.06 6 0.33
GM 1.06 6 0.25 0.85 6 0.18
PPAR-g BAT 1.18 6 0.46 0.67 6 0.28
GM 1.16 6 0.37 0.73 6 0.32
Dio2 BAT 1.02 6 0.15 0.73 6 0.31
GM 1.00 6 0.05 1.01 6 0.46
Results are means 6 SEM. n = 6, relative to TRPV1 WT mice.
***P , 0.001 TRPV1 KO vs. TRPV1 WT as determined by 2-tailed
Student’s t test.




acute BAT activation following
TRPV1 antagonist-induced hyper-
thermia. Sensory nerves and sym-
pathetic nerves innervate BAT,
suggested to mediate feedback
loops serving a proposed pathway
for crosstalk. Brown adipocytes
have been shown to express TRP
channels, including TRPV1 (58).
AMG9810 transiently disrupts
this feedback loop (1), causing
hyperthermia mediated via an
increase in sympathetic activity
and NA release (2). NA stimulates
b-adrenoceptors and initiates
downstream signaling resulting
in heat generation. SN-SS, sen-
sory nerve-sympathetic system;
TG, triglyceride; FFA, free
fatty acid.
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of various proteins, involved in thermogenesis, that are
under sympathetic control in BAT and skeletal muscle.
UCP1 is the most potent thermogenic protein in mam-
mals, but neither its mRNA nor protein levels were sig-
nificantly altered in BAT from AMG9810-treated mice.
These results suggest that if UCP1 is involved in the hy-
perthermia induced by acute TRPV1 inhibition, then
UCP1 activity is probably altered, as opposed to UCP1
expression, at least during the first hour after AMG9810
administration. Protein levels of the skeletal muscle-
abundant homolog, UCP3, were increased inGMmuscle
of the same animals, which is interesting considering the
pivotal role that UCP3 plays in amphetamine-mediated
thermogenesis (33).
Despite a lack of change in UCP1 mRNA and protein
levels, a significant induction in the mRNA expression of
downstream signaling mediators such as PGC1-a was de-
termined in BAT samples from AMG9810-treated mice. It
is known that the expressionofUCP1 is highlyfluidic and is
driven by several transcriptional components, including
PGC1-a (34). PGC1-a is known to regulate oxidative me-
tabolism by increasingmitochondrial gene expression and
function (35). PPAR-g, a regulator of UCP1 expression
(34), was modestly increased by AM9810. In contrast,
a significant induction of Dio2 was observed, implicating
the HPT axis in AMG9810-induced hyperthermia (50).
Dio2 has been shown to be an essential component in the
thyroid-sympathetic synergism in BAT-mediated thermo-
genesis (51); a significant induction in Dio2 has been
shown during cold exposure, which facilitates the accel-
erated conversion of the biologically inactive thyroxine
(T4) to 3,39,5-triiodothyronine (T3) (52, 53), which
increases adrenergic responsiveness in a positive feedback
mechanism (53). Additionally, Dio2 can directly act as
a transcriptional factor modulating UCP1 biogenesis (51).
Taken together, our results suggest that acutely, AMG9810
initiates a thermogenic response in BAT, which is in-
dicative of UCP1 activation.
TRPV1 KO mice exhibit suppressed peripheral
sympathetic activity
We subsequently sought to explore the thermoregulatory
profile of TRPV1 KO mice. The TRPV1 KO thermoregu-
latory phenotype has been explored before where basal
body temperature did not significantly differ from WT
mice, suggesting that a compensatory adjustment has been
made to regulate body temperature. As previously repor-
ted, we observed an increase in locomotor activity in KO
mice during the light phase of their light-dark cycle (18).
We also observed this hyperkinesis in TRPV1 KO mice,
whereas both groups exhibited equal levels of nocturnal,
dark-phaseactivity.Thehyperactivityhasbeensuggestedas
a compensatory mechanism for the altered thermo-
regulatory profile these mice display when thermally
challenged (18). In addition to activity changes, we
hypothesized that SNS activity is suppressed in TRPV1
KO mice.
To test sympathetic dysfunction in TRPV1 KO mice,
the sympathomimetic drug, D-amphetamine, was utilized
to assess the temperature responses in these mice.
TRPV1 KOmice demonstrated a significantly attenuated
hyperthermia during the period in which hyperthermia
was significant in WT animals. Amphetamine adminis-
tration has previously been shown to increase both BAT
and rectal temperature in amanner that can be inhibited
with propranolol (54), similar to the findings with
AMG9810. In the present study, D-amphetamine caused
a significant increase in activity in bothTRPV1WTandKO
mice, indicating that any difference in body temperature
between the 2 genotypes cannot solely be accounted for by
changes in activity levels. In addition, it may suggest that
the effect of D-amphetamine on body temperature is
sympathetically mediated, whereas the effect on activity is
not. Indeed, it is well known that amphetamine induces
dopamine release in the nucleus accumbens of the brain,
a region associated with dopamine-induced locomotor
activity. Furthermore, it was reported that amphetamine-
induced hyperactivity and dopamine release are en-
hanced in mice lacking the M(5) receptor, suggesting
a role formuscarinic receptors in theprocess (55).Overall,
the results in this component of the present study showed
a reduced capacity of TRPV1 KO animals to respond to
a sympathomimetic drug, suggesting that sympathetic
drive has been reduced as a compensatory mechanism to
normalize body temperature in these animals.
As sympathetic activity in TRPV1 KO animals appeared
to be reduced, we carried out experiments to test whether
NA levels in brain, skin, and BAT from KO animals were
lower than those of their WT counterparts. The NA con-
centration measured in brain and BAT samples did not
significantly differ between WT and KO animals, but NA
concentrations in skin samples of TRPV1 KO mice were
significantly decreased compared to WT controls, sug-
gesting a compensatory decrease in NA production or
metabolism. AsBATNAcontent was not different between
the 2 groups, we sought to assess the thermogenic capacity
of BAT by measurement of UCP1 content. The results il-
lustrated a trend toward decreased UCP1 expression in
mitochondrial extracts ofBATsamplesofTRPV1KOmice,
compared to WT controls. Interestingly, similar results
were documented in sensory nerve-depleted rats (5), in-
dicating an important role for sensory nerves and TRPV1
channels in maintaining BAT homeostasis. Intrascapular
BAT weight was significantly increased in TRPV1 KOmice
along with morphologic changes (i.e., a whitening pheno-
type in KOs), with increased lipid deposition and size. This
increased lipidization is known to be associated with re-
duced b-adrenoceptor signaling, associated with reduced
sympathetic activity (31).
In conclusion, this study confirms previous findings that
TRPV1 plays a pivotal role in the regulation of body tem-
perature. New evidence from the present study demon-
strates that TRPV1 is acting upstream of the SNS to exert
this effect. Acute removal of this regulatory activity via
administration of antagonists results in an increased
sympathetic drive and manifestation of hyperthermia.
Furthermore, genetic deletion of TRPV1 results in a com-
pensatory suppression of sympathetic activity and/or
associated thermoregulatory pathways. The fundamental
role of the SNS in thermoregulation has been known for
many years, but this is the first study to show that this
regulatory effect is controlled by TRPV1 at a basal level,
providing a potential therapeutic target for hyper-
sympathetic thermoregulatory disorders.
4296 Vol. 29 October 2015 ALAWI ET AL.The FASEB Journal x www.fasebj.org
K.M.A. was supported by the Medical Research Council.
A.A.A., J.E.K., and L.L. were supported by a Biotechnology
and Biological Sciences Research Council Capacity Building
Award in Integrative Mammalian Biology. A.A.A. was further
supported by the British Heart Foundation. E.W. was supported
by the National Centre for Replacement, Reduction, and
Refinement.
REFERENCES
1. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A.,
Levine, J. D., and Julius, D. (1997) The capsaicin receptor:
a heat-activated ion channel in the pain pathway. Nature 389,
816–824
2. Tominaga,M., Caterina,M. J.,Malmberg, A. B., Rosen,T.A.,Gilbert,
H., Skinner, K., Raumann, B. E., Basbaum,A. I., and Julius,D. (1998)
The cloned capsaicin receptor integrates multiple pain-producing
stimuli. Neuron 21, 531–543
3. Gavva, N. R., Bannon, A. W., Surapaneni, S., Hovland, Jr., D. N.,
Lehto, S. G., Gore, A., Juan, T., Deng, H., Han, B., Klionsky, L.,
Kuang, R., Le, A., Tamir, R., Wang, J., Youngblood, B., Zhu, D.,
Norman, M. H., Magal, E., Treanor, J. J., and Louis, J. C. (2007) The
vanilloid receptorTRPV1 is tonically activated in vivo and involved in
body temperature regulation. J. Neurosci. 27, 3366–3374
4. Gavva, N. R., Treanor, J. J., Garami, A., Fang, L., Surapaneni, S.,
Akrami, A., Alvarez, F., Bak, A., Darling, M., Gore, A., Jang, G. R.,
Kesslak, J. P., Ni, L., Norman, M. H., Palluconi, G., Rose, M. J., Salfi,
M., Tan, E., Romanovsky, A. A., Banfield, C., and Davar, G. (2008)
Pharmacological blockade of the vanilloid receptor TRPV1 elicits
marked hyperthermia in humans. Pain 136, 202–210
5. Yamashita,H.,Wang, Z.,Wang, Y., Furuyama,T., Kontani, Y., Sato, Y.,
and Mori, N. (2008) Impaired basal thermal homeostasis in rats
lacking capsaicin-sensitive peripheral small sensory neurons.
J. Biochem. 143, 385–393
6. Romanovsky, A. A., Almeida, M. C., Garami, A., Steiner, A. A.,
Norman, M. H., Morrison, S. F., Nakamura, K., Burmeister, J. J., and
Nucci, T. B. (2009) The transient receptor potential vanilloid-1
channel in thermoregulation: a thermosensor it is not. Pharmacol.
Rev. 61, 228–261
7. Lowell, B. B., and Spiegelman, B. M. (2000) Towards a molecular
understanding of adaptive thermogenesis. Nature 404, 652–660
8. Cannon, B., and Nedergaard, J. (2004) Brown adipose tissue:
function and physiological significance. Physiol. Rev. 84, 277–359
9. Milner, R. E., Wang, L. C., and Trayhurn, P. (1989) Brown fat
thermogenesis during hibernation and arousal in Richardson’s
ground squirrel. Am. J. Physiol. 256, R42–R48
10. Nedergaard, J., Bengtsson, T., and Cannon, B. (2007) Unexpected
evidence for active brown adipose tissue in adult humans. Am. J.
Physiol. Endocrinol. Metab. 293, E444–E452
11. Sacks,H., andSymonds,M.E. (2013)Anatomical locationsofhuman
brown adipose tissue: functional relevance and implications in
obesity and type 2 diabetes. Diabetes 62, 1783–1790
12. Cypess, A. M., Weiner, L. S., Roberts-Toler, C., Franquet Eĺıa, E.,
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